TICKERNOMICS Sign up
Last Update: 2024-03-28 02:11:30
Mirum Pharmaceuticals Inc. ( MIRM ) https://www.mirumpharma.com
24.91USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
MIRM
8.80%
SPY
32.74%
MIRM
34.11%
SPY
92.93%
MIRM
0.00%
SPY
224.41%
MIRM
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1220.88
1219.63
0.36
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-7.44
8.44
4.91
-8.72
0.00
-5.13
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-52.69
78.57
-144.37
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-28.06
-23.73
0.00
Other Earnings and Cash Flow Stats:
Mirum Pharmaceuticals Inc. ( MIRM ) Net Income TTM ($MM) is -125.85
Mirum Pharmaceuticals Inc. ( MIRM ) Operating Income TTM ($MM) is -119.34
Mirum Pharmaceuticals Inc. ( MIRM ) Owners' Earnings Annual ($MM) is 0.00
Mirum Pharmaceuticals Inc. ( MIRM ) Current Price to Owners' Earnings ratio is 0.00
Mirum Pharmaceuticals Inc. ( MIRM ) EBITDA TTM ($MM) is -159.81
Mirum Pharmaceuticals Inc. ( MIRM ) EBITDA Margin is -144.37%
Capital Allocation:
Mirum Pharmaceuticals Inc. ( MIRM ) has paid 0.00 dividends per share and bought back -12.74065 million shares in the past 12 months
Mirum Pharmaceuticals Inc. ( MIRM ) has reduced its debt by 0.467 million USD in the last 12 months
Capital Structure:
Mirum Pharmaceuticals Inc. ( MIRM ) Interest-bearing Debt ($MM) as of last quarter is 1
Mirum Pharmaceuticals Inc. ( MIRM ) Annual Working Capital Investments ($MM) are -5
Mirum Pharmaceuticals Inc. ( MIRM ) Book Value ($MM) as of last quarter is 248
Mirum Pharmaceuticals Inc. ( MIRM ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Mirum Pharmaceuticals Inc. ( MIRM ) has 286 million in cash on hand as of last quarter
Mirum Pharmaceuticals Inc. ( MIRM ) has 87 million of liabilities due within 12 months, and long term debt 306 as of last quarter
Mirum Pharmaceuticals Inc. ( MIRM ) has 46 common shares outstanding as of last quarter
Mirum Pharmaceuticals Inc. ( MIRM ) has 0 million USD of preferred stock value
Academic Scores:
Mirum Pharmaceuticals Inc. ( MIRM ) Altman Z-Score is 0.93 as of last quarter
Mirum Pharmaceuticals Inc. ( MIRM ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
Mirum Pharmaceuticals Inc. ( MIRM ) largest shareholder is Vanguard Group Inc owning 1693343 shares at 42.17 ($MM) value
Radovich Peter(an insider) Sold 4303 shares of Mirum Pharmaceuticals Inc. ( MIRM ) for the amount of $111017.40 on 2024-03-25
4.17% of Mirum Pharmaceuticals Inc. ( MIRM ) is held by insiders, and 84.83% is held by institutions
Mirum Pharmaceuticals Inc. ( MIRM ) went public on 2019-07-18
Other Mirum Pharmaceuticals Inc. ( MIRM ) financial metrics:
FCF:-98.14
Unlevered Free Cash Flow:-98.11
EPS:-2.02
Operating Margin:-52.69
Gross Profit Margin:78.57
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-37.94
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Mirum Pharmaceuticals Inc. ( MIRM ) :
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.